Gainers

• PepGen (NASDAQ:PEPG) stock rose 126.6% to $5.42 during Tuesday's regular session. The company's market cap stands at $165.5 million. The company's, Q3 earnings came out today.
• Nano X Imaging (NASDAQ:NNOX) stock increased by 35.31% to $0.32. The company's market cap stands at $18.3 million.
• Longeveron (NASDAQ:LGVN) stock increased by 30.34% to $2.62. The market value of their outstanding shares is at $6.4 million.
• Estrella Immunopharma (NASDAQ:ESLA) shares rose 25.25% to $0.64. The company's market cap stands at $22.3 million.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock moved upwards by 24.31% to $0.18.
• Humacyte (NASDAQ:HUMA) stock rose 21.94% to $0.56. The market value of their outstanding shares is at $126.4 million. As per the news, the Q3 earnings report came out today.

Losers

• Karyopharm Therapeutics (NASDAQ:KPTI) shares decreased by 42.5% to $0.02 during Tuesday's regular session.
• Tessera Defense (AMEX:HLSQ) stock fell 37.44% to $0.07. The market value of their outstanding shares is at $2.3 million.
• Exagen (NASDAQ:XGN) shares decreased by 28.6% to $5.07. The company's market cap stands at $171.5 million. The company's, Q3 earnings came out today.
• Cosmos Health (NASDAQ:COSM) stock declined by 26.59% to $0.2. The company's market cap stands at $26.9 million.
• P3 Health Partners (NASDAQ:PIII) stock fell 24.95% to $3.19. The market value of their outstanding shares is at $16.6 million. The company's, Q3 earnings came out yesterday.
• Coherus Oncology (NASDAQ:CHRS) stock declined by 22.44% to $0.63. The market value of their outstanding shares is at $126.3 million. As per the news, the Q3 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.